Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

被引：197

作者：

Hantschel, Oliver ^{[1
]}

Rix, Uwe ^{[1
]}

Superti-Furga, Giulio ^{[1
]}

机构：

[1] Austrian Acad Sci, Ctr Mol Med, A-1090 Vienna, Austria

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 04期

关键词：

BCR-ABL; imatinib; drug targets; chemical proteomics;

D O I：

10.1080/10428190801896103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.

引用

页码：615 / 619

页数：5

共 50 条

[41] Off-Target Effects of BCR-ABL and JAK2 Inhibitors
Green, Myke R.
Newton, Michael D.
Fancher, Karen M.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01): : 76 - 84
[42] New strategies to target Bcr-Abl with ATP-competitive and allosteric inhibitors
Hantschel, O.
ONKOLOGIE, 2012, 35 : 199 - 199
[43] CRKL binding to BCR-ABL and BCR-ABL transformation
Kolibaba, KS
Bhat, A
Heaney, C
Oda, T
Druker, BJ
LEUKEMIA & LYMPHOMA, 1999, 33 (1-2) : 119 - 126
[44] Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Haouala, Amina
Widmer, Nicolas
Duchosal, Michel A.
Montemurro, Michael
Buclin, Thierry
Decosterd, Laurent A.
BLOOD, 2011, 117 (08) : E75 - E87
[45] Broad spectrum alkynyl inhibitors of T315I Bcr-Abl
Deng, Xianming
Lim, Sang Min
Zhang, Jianming
Gray, Nathanael S.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (14) : 4196 - 4200
[46] The inhibition of ABL kinase activity of nilotinib and imatinib, but not dasatinib, is time-dependent
Manley, Paul
Cowan-Jacob, Sandra
Fendrich, Gabriele
Liebetanz, Janis
Mestan, Jurgen
Martin, Nicole
Fabbro, Doriano
CANCER RESEARCH, 2009, 69
[47] Osteopontin is a target of BCR-ABL oncogene.
Flamant, S
Kortulewski, T
Dugray, A
Bonnet, ML
Guillier, M
Guilhot, F
Bourhis, JH
Vainchenker, W
Le Roux, D
Turhan, AG
BLOOD, 2003, 102 (11) : 139A - 139A
[48] Mechanisms of Resistance to BCR-ABL Kinase Inhibitors
Diamond, Joana
da Silva, Maria Gomes
ACTA MEDICA PORTUGUESA, 2013, 26 (04): : 402 - 408
[49] Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias
Jabbour, Elias
El Ahdab, Samih
Cortes, Jorge
Kantarjian, Hagop
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 1127 - 1136
[50] Spectrum of BCR-ABL Kinase Domain Mutations in North Macedonia in Patients With CML Resistant to Imatinib
Stojanovska-Jakimovska, Simona
Cvetanoski, Milche
Ridova, Nevenka
Trajkova, Sanja
Popova-Labachevska, Marija
Mojsovska, Tara
Dukovski, Dushko
Pivkova-Veljanovska, Aleksandra
Stojanovski, Zlate
Krstevska-Balkanov, Svetlana
Pavkovic, Marica
Chadievski, Lazar
Panovska-Stavridis, Irina
Ivanovski, Martin
Gjorgievska, Emilija
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S375 - S375

← 1 2 3 4 5 →